Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business cove… Read more
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) - Total Liabilities
Latest total liabilities as of June 2025: CN¥1.29 Billion CNY
Based on the latest financial reports, Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has total liabilities worth CN¥1.29 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Competitors by Total Liabilities
The table below lists competitors of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guardian Capital Group Limited
PINK:GRCGF
|
USA | $748.64 Million |
|
Xiamen Insight Investment Co Ltd
SHE:000526
|
China | CN¥3.26 Billion |
|
RLH Properties S.A.B. de C.V
MX:RLHA
|
Mexico | MX$23.47 Billion |
|
Kaleseramik Canakkale Kalebodur Seramik Sanayi A.S.
IS:KLSER
|
Turkey | TL7.60 Billion |
|
Ningbo Cixing
SHE:300307
|
China | CN¥1.21 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥247.20 Million |
|
Dioo Microcircuits Co. Ltd. Jiangsu A
SHG:688381
|
China | CN¥195.26 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2024)
The table below shows the annual total liabilities of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.14 Billion | +15.92% |
| 2023-12-31 | CN¥984.97 Million | +120.13% |
| 2022-12-31 | CN¥447.45 Million | -26.30% |
| 2021-12-31 | CN¥607.10 Million | +90.19% |
| 2020-12-31 | CN¥319.20 Million | +219.55% |
| 2019-12-31 | CN¥99.89 Million | -- |